NanoMedSyn develops a new delivery platform to create first-in-class drugs by the engineering with patented AMFA vectors of antibodies, enzymes or nanoparticles. These AMFA-modified therapeutics will target patients suffering from lysosomal storage disorders, cancers, inflammatory or immune diseases.
Our objectives
Based on AMFA
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
The main application
is the engineering of recombinant proteins like antibodies or enzymes for better therapies.
Development
NanoMedSyn develops engineered therapeutics in-house and in partnership.